Robert Lorne Hopfner

CIK: 0001551966

Transaction Breakdown

Open Market Buys (P)1 (8.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)3 (25.0%)

Derivative conversions

Awards (A)2 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)6 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

RLYB

Rallybio Corp

Director

EVMN

Evommune, Inc.

Director10% Owner

INZY

Inozyme Pharma, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (12 total)

RLYB
Rallybio Corp
Oct 12, 2026
Exercise(M)
Direct
3.6K shares at avg. $2.38$8K
RLYB
Rallybio Corp
Oct 12, 2026
Exercise(M)
Direct
2.1K shares at avg. $15.28$32K
RLYB
Rallybio Corp
Oct 12, 2026
Exercise(M)
Direct
9.2K shares at avg. $7.60$70K
EVMN
Evommune, Inc.
Dec 19, 2025
Purchase(P)
Indirect
1K shares at avg. $17.35$17K
EVMN
Evommune, Inc.
Nov 7, 2025
Conversion(C)
Indirect
3K shares-
EVMN
Evommune, Inc.
Nov 7, 2025
Conversion(C)
Indirect
1.4M shares-
EVMN
Evommune, Inc.
Nov 7, 2025
Conversion(C)
Indirect
1.6M shares-
EVMN
Evommune, Inc.
Nov 7, 2025
Conversion(C)
Indirect
294.5K shares-
INZY
Inozyme Pharma, Inc.
Jul 1, 2025
Tender Offer(U)
Indirect
1.6M shares at avg. $4.00$6.3M
INZY
Inozyme Pharma, Inc.
Jul 1, 2025
Tender Offer(U)
Indirect
2.9M shares at avg. $4.00$11.7M
RLYB
Rallybio Corp
May 13, 2025
Award(A)
Option (Right to Buy)
Direct
28.5K shares-
RLYB
Rallybio Corp
Jan 2, 2025
Award(A)
Option (Right to Buy)
Direct
73.6K shares at avg. $0.70-

		Type	Shares	Price		Ownership
Oct 12, 2026	RLYB Rallybio Corp	Exercise(M)	3,562	$2.38	$8,478	Direct
Oct 12, 2026	RLYB Rallybio Corp	Exercise(M)	2,062	$15.28	$31,507	Direct
Oct 12, 2026	RLYB Rallybio Corp	Exercise(M)	9,196	$7.60	$69,890	Direct
Dec 19, 2025	EVMN Evommune, Inc.	Purchase(P)	1,000	$17.35	$17,350	Indirect
Nov 7, 2025	EVMN Evommune, Inc.	Conversion(C)	3,026	-	-	Indirect
Nov 7, 2025	EVMN Evommune, Inc.	Conversion(C)	1,441,032	-	-	Indirect
Nov 7, 2025	EVMN Evommune, Inc.	Conversion(C)	1,632,441	-	-	Indirect
Nov 7, 2025	EVMN Evommune, Inc.	Conversion(C)	294,502	-	-	Indirect
Jul 1, 2025	INZY Inozyme Pharma, Inc.	Tender Offer(U)	1,571,741	$4.00	$6,286,964	Indirect
Jul 1, 2025	INZY Inozyme Pharma, Inc.	Tender Offer(U)	2,923,110	$4.00	$11,692,440	Indirect
May 13, 2025	RLYB Rallybio Corp	Award(A) Option (Right to Buy)	28,500	-	-	Direct
Jan 2, 2025	RLYB Rallybio Corp	Award(A) Option (Right to Buy)	73,571	$0.70	-	Direct

1-12 of 12 transactions

About Hopfner Robert Lorne

Hopfner Robert Lorne (SEC CIK 0001551966) files insider reports with the SEC as Director of Rallybio Corp (RLYB), Director of Evommune, Inc. (EVMN) and Director of Inozyme Pharma, Inc. (INZY).

Signal8 holds 7 ownership filings by Hopfner Robert Lorne (1 Form 3, 6 Form 4), filed between Jan 6, 2025 and Oct 14, 2026. Those filings report 12 transactions, from Jan 2, 2025 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hopfner Robert Lorne's filings is in EAST BERLIN, CT.

Recent filings by Hopfner Robert Lorne

Oct 12, 2026: Option exercises of RLYB shares (3 lines, Form 4, code M).
Dec 19, 2025: Open-market purchase of EVMN shares (Form 4, code P).
Nov 7, 2025: Conversions of EVMN shares (4 lines, Form 4, code C).
Jul 1, 2025: Tender of shares transactions of INZY shares (2 lines, Form 4, code U).
May 13, 2025: Grant or award of RLYB derivative securities (Form 4, code A).

Other insiders filing for Rallybio Corp (RLYB)

Lieber Jonathan I, Chief Financial Officer
HUNT RONALD, Director
Nash Christine A, Director
Uden Stephen, Chief Executive Officer
Chung Wendy, Director
Soteropoulos Paula, Director

How to read Form 4 transaction codes